PREMOST organoid-based trial open for enrollment
February 1, 2024
Our very first clinical trial that leverages patient-derived tumor organoids in osteosarcoma is officially open and enrolling! PREMOST, An Organoid-based Functional Precision Medicine Trial in Osteosarcoma (NCT06064682) is open to patients of any age with either a suspect osteosarcoma diagnosis (Arm 1) or recurrent/metastatic osteosarcoma (Arm 2). We will test feasibility to develop organoids from these cases and determine the prognostic power of the assay as well as return results to the clinic through our sarcoma tumor board.
READ MORE